Literature DB >> 17997806

Use of dry powder inhalers in COPD.

D S Wilson1, M S Gillion, P J Rees.   

Abstract

INTRODUCTION: This was a study of 30 chronic obstructive pulmonary disease (COPD) patients to assess the ease of use and preference of four dry powder inhalers -- accuhaler, aerolizer, handihaler, turbohaler -- the accuhaler and turbohaler are multidose devices, whereas the aerolizer and handihaler are single dose devices.
METHOD: None of the subjects had previous experience of dry powder inhalers. The correct technique for each inhaler was divided into 12 steps including one critical step that if not performed would result in no drug delivery. Subjects were shown the correct technique for each inhaler in a random order and were assessed immediately and 1 h later. Each subject was asked to rank the four devices for preference and ease of use, as well as to assess how comfortable it felt to inhale through the device using a visual analogue scale.
RESULTS: The numbers of perfect scores were not significantly different between devices, but the number of fatal errors that would result in no drug delivery was significantly more common in single dose devices (p < 0.01). There were significant differences in the rankings of each device (Friedman test, p < 0.005) with the turbohaler being ranked first most often and the handihaler last. The turbohaler scored highest for comfort of inhalation and the accuhaler lowest, but differences were small.
CONCLUSIONS: In COPD patients starting on dry powder inhalers, multidose devices appear to be preferred, have fewer problems and are easier to use effectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997806     DOI: 10.1111/j.1742-1241.2007.01593.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  7 in total

1.  Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners.

Authors:  Mathieu Molimard; Paul Colthorpe
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-09-29       Impact factor: 2.849

Review 2.  Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.

Authors:  Luis Javier Nannini; Phillippa Poole; Stephen J Milan; Rebecca Holmes; Rebecca Normansell
Journal:  Cochrane Database Syst Rev       Date:  2013-11-10

Review 3.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.

Authors:  Luis Javier Nannini; Phillippa Poole; Stephen J Milan; Annabel Kesterton
Journal:  Cochrane Database Syst Rev       Date:  2013-08-30

4.  Pitfalls associated with the therapeutic reference pricing practice of asthma medication.

Authors:  Zoltan Kalo; Zsolt Abonyi-Toth; Zoltan Bartfai; Zoltan Voko
Journal:  BMC Pulm Med       Date:  2012-07-20       Impact factor: 3.317

5.  Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain.

Authors:  Josep Darbà; Gabriela Ramírez; Juan L García-Rivero; Sagrario Mayoralas; José Francisco Pascual; Diego Vargas; Adi Bijedic
Journal:  Clinicoecon Outcomes Res       Date:  2017-02-10

Review 6.  Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting.

Authors:  Barbara P Yawn; Gene L Colice; Rick Hodder
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-25

7.  Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).

Authors:  Ariane K Kawata; Leah Kleinman; Gale Harding; Sulabha Ramachandran
Journal:  Patient       Date:  2014       Impact factor: 3.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.